Literature DB >> 11791001

Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: different anti-proliferative effect to angiotensin-converting enzyme inhibitor.

Jian Teng1, Noboru Fukuda, Ryo Suzuki, Hiroto Takagi, Yukihiro Ikeda, Yoshiko Tahira, Katsuo Kanmatsuse.   

Abstract

The current study was undertaken to evaluate the anti-proliferative effect of a novel angiotensin II type 1 (AT1) receptor antagonist, RNH-6270, on exaggerated growth of vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR), in comparison with the effects of an angiotensin-converting enzyme (ACE) inhibitor. RNH-6270 and temocapril significantly inhibited basal DNA synthesis in VSMCs from SHRs in a dose-dependent manner, but not in cells from Wistar-Kyoto (WKY) rats. SHR-derived VSMC showed a hyperresponse of DNA synthesis to serum and angiotensin II compared with that of WKY rats-derived VSMC. RNH-6270 did not affect serum-stimulated DNA synthesis in VSMCs from both rat strains. RNH-6270 abolished angiotensin II-stimulated DNA synthesis in VSMC from both rat strains. RNH-6270 significantly inhibited proliferation of VSMC from both rat strains, but the ACE inhibitor temocapril did not exert such an effect. RNH-6270 decreased the specific binding of angiotensin II to VSMC in a competitive manner for angiotensin II receptors in both rat strains. RNH-6270 and temocapril significantly decreased the expression of growth factor mRNAs and proteins in VSMC from SHR, but not in cells from WKY rats. These results suggest that RNH-6270 is a potent AT1 receptor antagonist and has anti-proliferative effects on VSMCs from SHR, which was not seen with an ACE inhibitor. The growth inhibitory effect of RNH-6270 may be associated with the inhibition of growth factors via antagonism to AT1 receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11791001     DOI: 10.1097/00005344-200202000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury.

Authors:  Daisuke Kadowaki; Makoto Anraku; Moe Sakaya; Sumio Hirata; Toru Maruyama; Masaki Otagiri
Journal:  Clin Exp Nephrol       Date:  2015-04-23       Impact factor: 2.801

2.  Young Scholars Award Lecture: Intratubular angiotensinogen in hypertension and kidney diseases.

Authors:  Hiroyuki Kobori; Yuri Ozawa; Yuki Suzaki; Minolfa C Prieto-Carrasquero; Akira Nishiyama; Tatsuya Shoji; Eric P Cohen; L Gabriel Navar
Journal:  Am J Hypertens       Date:  2006-05       Impact factor: 2.689

3.  Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats.

Authors:  Hiroyuki Kobori; Yuri Ozawa; Yuki Suzaki; Akira Nishiyama
Journal:  J Am Soc Nephrol       Date:  2005-05-11       Impact factor: 10.121

4.  Angiotensin II or epinephrine hemodynamic and metabolic responses in the liver of L-NAME induced hypertension and spontaneous hypertensive rats.

Authors:  Debora Conte Kimura; Marcia Regina Nagaoka; Durval Rosa Borges; Maria Kouyoumdjian
Journal:  World J Hepatol       Date:  2017-06-18

5.  Down-regulation of Suv39h1 attenuates neointima formation after carotid artery injury in diabetic rats.

Authors:  Jing Zhang; Jian Yang; Changwu Xu; Qi Hu; Jun Hu; Jing Chen; Hong Jiang
Journal:  J Cell Mol Med       Date:  2019-11-17       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.